Home/Pipeline/Perampanel

Perampanel

Epilepsy

In DevelopmentActive

Key Facts

Indication
Epilepsy
Phase
In Development
Status
Active
Company

About Ark Diagnostics

Ark Diagnostics is a commercial-stage diagnostics company with a core focus on homogeneous enzyme immunoassay technology for clinical chemistry analyzers. The company has established a diversified portfolio of ready-to-use liquid assays, primarily serving hospital and reference laboratories for therapeutic drug monitoring and forensic/clinical urine drug testing. Its strategy involves continuous assay development, with recent launches in ethyl glucuronide, ketamine, and methotrexate testing, and a pipeline expanding into areas like veterinary diagnostics and oral anticoagulants. Ark operates globally through a distributor network and maintains a presence at key scientific conferences.

View full company profile

Other Epilepsy Drugs

DrugCompanyPhase
ADX71149 (mGlu2 PAM)Addex TherapeuticsPhase 2
TRV045TrevenaPhase 1
SAGE-324Sage TherapeuticsPreclinical
Motpoly XR™Aucta PharmaceuticalsNot Specified (Likely Phase 3/NDA)
ADB-104Adolore BioTherapeuticsPre-clinical
Not Publicly DisclosedCerecinPhase 2
eTNS PlatformNeuroSigmaUnknown
NPT 2042NeuroPro TherapeuticsPhase 2
Spritam (levetiracetam)Aprecia PharmaceuticalsApproved
NeuroAccess PlatformCordance MedicalPre-clinical/Research
Epilepsy ProgramCurrent SurgicalResearch
GABA-A PAM for EpilepsyModulate BioPreclinical